Abdoulaye Karaboué
6PUBLICATIONS
24CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Dec 15, 2025
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.Pasquale F Innominato, Thierry Landré, Abdoulaye Karaboué
|Nov 07, 2024
Neo-wt-RAS in ctDNA: Is It Worth Using Anti-EGFR Therapies?Pasquale F Innominato, Abdoulaye Karaboué, Francis A Lévi
|Jun 04, 2024
Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?Abdoulaye Karaboué, Pasquale F Innominato, Nicholas I Wreglesworth
|Feb 25, 2022
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.Abdoulaye Karaboué, Thierry Collon, Ida Pavese
|Nov 27, 2016
Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project.Pasquale F Innominato, Sandra Komarzynski, Ali Mohammad-Djafari
Pageof 1
Frequent Collaborators
5 joint publications
Pasquale Innominato
5 joint publications
Francis Levi
1 joint publications
Sandra Komarzynski
1 joint publications
Ali Mohammad-Djafari
1 joint publications
Alexandre Arbaud
1 joint publications
Ayhan Ulusakarya
1 joint publications
Mohamed Bouchahda
1 joint publications
Mazen Haydar
1 joint publications
Rachel Bossevot-Desmaris
1 joint publications
Virginie Plessis
